Our guide to targeting your search
Search:

Refine your search

Filter By
Geography
District
Funder
Funding Organizations
Recipient
Recipient Organizations
Your search ‘’ returned 518 results in ‘All grant fields’

Search results (Displaying 518 grants)

Total grants
518
Total funders
19
Total recipients
338
Earliest award date
01 Jan 2017
Latest award date
06 Nov 2018
Export search data:
School Games Organiser Awards
Funding under Sport England's School Games funding programme for a Revenue project titled School Games Organiser Awards. This project is a Multi Sports project, with a focus on beneficiaries with a disability.
Amount: £10,710,000
Funder: Sport England
Recipient: Ecorys UK Limited
Region: West Midlands
NGB Funding 2017-21
Funding under Sport England's NGB Funding 2017-21 funding programme for a Revenue project titled NGB Funding 2017-21. This project lists its main activity as Rugby Union
Amount: £10,000,000
Funder: Sport England
Region: London
NGB Funding 2017-21
Funding under Sport England's NGB Funding 2017-21 funding programme for a Revenue project titled NGB Funding 2017-21. This project lists its main activity as Cycling
Amount: £12,018,000
Funder: Sport England
Region: North West
Football Facilities Investment 2017-20
Funding under Sport England's Football Foundation funding programme for a Capital project titled Football Facilities Investment 2017-20. This project lists its main activity as Association Football
Amount: £18,000,000
Funder: Sport England
Region: London
School Games Organiser Awards
Funding under Sport England's School Games funding programme for a Revenue project titled School Games Organiser Awards. This project is a Multi Sports project, with a focus on beneficiaries with a disability.
Amount: £10,710,000
Funder: Sport England
Recipient: Ecorys UK Limited
Region: West Midlands
Football Facilities Investment 2017-20
Funding under Sport England's Football Foundation funding programme for a Capital project titled Football Facilities Investment 2017-20. This project lists its main activity as Association Football
Amount: £18,000,000
Funder: Sport England
Region: London
World Mosquito Programme
The World Mosquito Program, formerly known as the Eliminate Dengue Program, is developing a new way to control dengue fever and other diseases caused by arboviruses including Zika and chikungunya. Dengue and these other diseases are caused by different viruses that are transmitted between people by mosquitoes. We have found that a common bacterium (Wolbachia) found in many insects naturally, but not the mosquito that transmits dengue, will reduce the ability of mosquitoes to transmit dengue and other viruses when it is introduced. Initial trials have demonstrated that the Wolbachia technology can be practically deployed at a limited scale, is stable in the field, is acceptable to communities and regulators, and is predicted by modeling to have a major impact on dengue transmission. We are undertaking large scale pilot deployments to demonstrate our ability to implement our Wolbachia vector control measures over significant population centres and also with the aim of providing evidence on disease impact. We are also building the infrastructure needed to support the scale-up and global roll-out of our Wolbachia technology. The technology, if it functions as envisioned, will provide an area-wide solution to the transmission of dengue and other arboviral diseases, capable of spreading and maintaining itself without the need for reapplication and without need for human behavior change.
Amount: £13,644,589
Recipient: Monash University
21st Century Treatments for the Sustainable Elimination of Leishmaniasis
The programme goal is to transform leishmaniasis treatment from the use of toxic, painful injectable antimonial therapies to a simple, orally acting and well tolerated treatment easy to use in resource poor settings. The strategy will rely on developing an oral combination of two co-administered drugs to maximise efficacy, reduce dose and duration of treatment, minimise side effects, and prevent or delay the emergence of drug resistance. DNDi, GlaxoSmithKline, the University of Dundee, Anacor, Pfizer, The Global Alliance for TB Drug Development, Takeda Pharmaceuticals and Celgene have built an unprecedented portfolio of candidates against Leishmania parasites. This pipeline is a strong basis for advancing towards oral leishmaniasis therapy(ies), to overcome attrition in development and identify one or more combination treatments for visceral leishmaniasis as the priority disease and also potentially for cutaneous leishmaniasis. This programme will evaluate 10 candidates aiming to select two orally-active New Chemical Entities (NCEs) ready for testing as a combination in Phase II studies in patients, maintaining a backup option of a combination of a single NCE with the existing oral drug, miltefosine. In the longer term, the programme aims to deliver new oral, high efficacy and affordable drug combinations for leishmaniasis.”
Amount: £10,044,444
THE COMBATING ANTIBIOTIC RESISTANT BACTERIA BIOPHARMACEUTICAL ACCELERATOR ‘CARB-X'
The Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) brings together leaders from industry, philanthropy, government and academia. It is a collaboration between the Biomedical Advanced Research and Development Authority (“BARDA”), the National Institute of Allergy and Infectious Diseases (“NIAID”), both within the US Department of Health and Human Services, and the Trustees of Boston University (“BU”). The international partnership will support a suite of products through early preclinical development. CARB-X aims to get products to a stage where private or public investors can then take them forward.
Amount: £124,959,820
Recipient: Boston University
Supporting various operational activities of the CEPI secretariat - main funding envelope
CEPI is in start-up phase until the end of 2017. During this period, an Interim Secretariat provided by the Government of Norway is coordinating CEPI activity with close support from the Government of India, Wellcome Trust, the Bill & Melinda Gates Foundation, and the World Economic Forum. John-Arne Røttingen, from the Norwegian Institute of Public Health, was appointed Interim Chief Executive Officer of CEPI in June 2016. A permanent CEO will be appointed Q1 2017. The Interim Board, with representatives from founding partners, industry, governments and non-governmental organisations, is chaired by K. Vijay Raghavan, Secretary of the Department of Biotechnology of India, and with Peter Piot, Director of the London School of Hygiene and Tropical Medicine, as vice-chair.
Amount: £80,680,175
To accelerate and drive forward the development of new medicines with an emphasis on addressing disease associated with the poor and developing world'
“The Global Health Innovative Technology Fund (GHIT Fund) is an international non-profit organization headquartered in Japan that invests in the discovery and development of new health technologies such as drugs, vaccines, and diagnostics for infectious diseases in developing nations . Wellcome Innovations Division contributes to the Fund alongside the Japanese Government, the Bill and Melinda Gates Foundation and six Japanese pharmaceutical companies.”
Amount: £10,396,257
Malawi Liverpool Wellcome Trust Programme - Core Award
<p>We will achieve internationally excellent translational science to benefit human health with a focus on sub-Saharan Africa.&nbsp; MLW is built around excellent laboratories, strategically located in the largest hospital in Malawi, closely linked with the community and an integral part of the medical school.&nbsp; These relationships provide a valuable opportunity replicated in few centres in Africa to study major health issues spanning both community and hospital.&nbsp; We will manage two major Programmes: (1) Preventing death from severe infection, and (2) Transmission reduction in infectious diseases and continue to publish over 100 papers/year.&nbsp; Over the next 5 years, we will target clinical syndromes of sepsis, meningitis, diarrhoea and pneumonia with vaccine, behavioural and clinical management strategies.&nbsp; We will focus on transmission of HIV, TB and malaria with improved access to care, diagnosis and treatment.&nbsp; In addition, a Strategic Initiative will target selected high burden chronic diseases (lung impairment, stroke, blindness), particularly related to HIV.&nbsp; In partnership with the College of Medicine we will deliver Training that will attract, train and retain local and international senior scientists.&nbsp; Through our partnership with the Ministry of Health, our Policy Aims will ensure that our research is both relevant and applied to improve human health.</p>
Amount: £25,084,066
UK Biobank
<p>As summarised in the extracted text below from our full application (page 5 "Proposed work") in Section 10 of this application form (and described in more detail on pages 5-16 of Section 10).</p> <p>&nbsp;</p> <p>During the next 5 years, it is intended to:</p> <ul> <li>&nbsp;Extend cohort-wide linkage to primary care health records, while maintaining and updating health outcome data from existing linkages to death, cancer and hospital records (and explore the added value of linkages to additional healthcare datasets);&nbsp;</li> <li>Further develop and implement large-scale identification and characterization of many different types of health outcome;</li> <li>Streamline the research access systems, and improve methods for processing, presenting and providing linked healthcare data to researchers;&nbsp;</li> <li>Maintain the sample resource, and make increasing amounts of different types of genotype and biomarker data available;&nbsp;</li> <li>Conduct imaging assessments in 100,000 participants, and develop and implement further enhancements (such as cardiac monitoring and further sample collection and assays).</li> </ul> <p>&nbsp;</p> <p>Efforts will continue to be made to ensure that researchers from around the world are suitably well informed about the resource so that the effective use of it increases substantially, leading to novel findings that have a major impact on human health.</p>
Amount: £31,700,000
Recipient: UK Biobank Ltd
Grant to The British Academy
Major research funding initiative 2018
Amount: £10,000,000
Recipient: The British Academy
Region: London
Grant to Hull City Council
Hull: Yorkshire’s Maritime City
Amount: £14,999,900
Recipient: Hull City Council
Grant to Aberystwyth Uni (Old College)
Bywyd Newydd i’r Hen Goleg / New Life for Old College
Amount: £10,581,800
Region: Wales
The Assuring Autonomy International Programme
The Assuring Autonomy International Programme will be a collaboration dedicated to enabling the benefits of Robotics and Autonomous Systems to be realised, whilst reducing attendant risks, e.g. from malfunction or cyber-attack. It will enhance design and assurance capabilities, validate them through translational demonstrators, and develop professional education programmes, engaging the industrial, regulatory and academic communities.
Amount: £10,000,000
Recipient: University of York
District: York
Discovering Safety
This proposal seeks to establish a significant programme of work with the Lloyds Register Foundation, which will be led by the UK’s Health and Safety Executive (HSE) and delivered through the International Institute for Risk and Regulatory Research. The programme will be focussed on “creating intelligence by understanding failure so that life is protected.
Amount: £10,000,000
Region: North West
District: Sefton District
Endangered Archives Programme
To continue to support the Endangered Archives Programme.
Amount: USD 12,000,000
Funder: ARCADIA
Recipient: British Library
Marine Wildlife Protection
To protect and restore marine life and ecosystems in some of the most biodiverse areas of the oceans through policy changes at the national and regional levels
Amount: USD 10,500,000
Funder: ARCADIA
Recipient: Oceana